JP2016521280A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016521280A5 JP2016521280A5 JP2016512061A JP2016512061A JP2016521280A5 JP 2016521280 A5 JP2016521280 A5 JP 2016521280A5 JP 2016512061 A JP2016512061 A JP 2016512061A JP 2016512061 A JP2016512061 A JP 2016512061A JP 2016521280 A5 JP2016521280 A5 JP 2016521280A5
- Authority
- JP
- Japan
- Prior art keywords
- lymphoma
- pharmaceutical composition
- composition according
- cell
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 8
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 8
- -1 quinazolinone compound Chemical class 0.000 claims 6
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 5
- 206010025323 Lymphomas Diseases 0.000 claims 5
- 208000003950 B-cell lymphoma Diseases 0.000 claims 3
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 201000003444 follicular lymphoma Diseases 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 210000003800 pharynx Anatomy 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000010962 ALK-positive anaplastic large cell lymphoma Diseases 0.000 claims 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000023611 Burkitt leukaemia Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 102000038030 PI3Ks Human genes 0.000 claims 1
- 108091007960 PI3Ks Proteins 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 108091008611 Protein Kinase B Proteins 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical class [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000000133 brain stem Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 210000000038 chest Anatomy 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 210000001280 germinal center Anatomy 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 1
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- KXBDTLQSDKGAEB-UHFFFAOYSA-N n-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound C1=CC(OCCOC)=CC=C1NC1=NC=C(F)C(NC=2C=C(NC(=O)C=C)C=CC=2)=N1 KXBDTLQSDKGAEB-UHFFFAOYSA-N 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 210000004180 plasmocyte Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361819384P | 2013-05-03 | 2013-05-03 | |
| US61/819,384 | 2013-05-03 | ||
| US201361908635P | 2013-11-25 | 2013-11-25 | |
| US61/908,635 | 2013-11-25 | ||
| PCT/US2014/036520 WO2014179661A1 (en) | 2013-05-03 | 2014-05-02 | Methods for treating cancer using combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016521280A JP2016521280A (ja) | 2016-07-21 |
| JP2016521280A5 true JP2016521280A5 (enExample) | 2017-06-15 |
Family
ID=50842385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016512061A Pending JP2016521280A (ja) | 2013-05-03 | 2014-05-02 | 併用療法を用いて癌を治療する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9119854B2 (enExample) |
| EP (1) | EP2991651A1 (enExample) |
| JP (1) | JP2016521280A (enExample) |
| TW (1) | TW201534305A (enExample) |
| WO (1) | WO2014179661A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3239144A1 (en) | 2006-09-26 | 2017-11-01 | Celgene Corporation | 5-substituted quinazolinone derivatives as anti-cancer agents |
| PH12013501821A1 (en) | 2011-03-11 | 2019-06-03 | Celgene Corp | Solid forms of 3-(5-amino-2methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses |
| CN104755472A (zh) | 2012-09-04 | 2015-07-01 | 细胞基因公司 | 3-(5-氨基-2-甲基-4-氧代喹唑啉-3(4h)-基)哌啶-2,6-二酮的同位素体及其制备方法 |
| US9126950B2 (en) | 2012-12-21 | 2015-09-08 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| US10272083B2 (en) * | 2014-01-21 | 2019-04-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
| HK1231381A1 (zh) * | 2014-07-11 | 2017-12-22 | Celgene Corporation | 癌症组合疗法 |
| EP3304076A4 (en) * | 2015-06-02 | 2018-12-19 | Celgene Corporation | Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins |
| WO2017004532A1 (en) * | 2015-07-02 | 2017-01-05 | Celgene Corporation | Combination therapy for treatment of hematological cancers and solid tumors |
| WO2017053555A1 (en) * | 2015-09-25 | 2017-03-30 | Celgene Corporation | Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs |
| BR112018013761A2 (pt) | 2016-01-08 | 2018-12-11 | Celgene Corp | compostos antiproliferativos e suas composições farmacêuticas e usos |
| WO2017120446A1 (en) * | 2016-01-08 | 2017-07-13 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
| SG11201805777QA (en) | 2016-01-08 | 2018-08-30 | Celgene Corp | Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
| US10189808B2 (en) * | 2016-01-08 | 2019-01-29 | Celgene Corporation | Solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses |
| KR102735378B1 (ko) * | 2018-11-09 | 2024-11-27 | 한국화학연구원 | 신규한 피페리딘-2,6-디온 유도체 및 이의 용도 |
| CN113151358B (zh) * | 2020-12-31 | 2024-02-20 | 洛阳市中心医院（郑州大学附属洛阳中心医院） | Znf382稳定转染的弥漫大b细胞淋巴瘤细胞株构建方法及应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7151164B2 (en) | 2002-02-14 | 2006-12-19 | Immunomedics, Inc. | Anti-CD20 antibodies and fusion proteins thereof and methods of use |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
| US8147832B2 (en) | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
| EP2143795B1 (en) | 2005-03-31 | 2011-07-20 | Biomedics Inc. | Anti-CD20 monoclonal antibody |
| WO2006130458A2 (en) | 2005-06-02 | 2006-12-07 | Astrazeneca Ab | Antibodies directed to cd20 and uses thereof |
| EP3239144A1 (en) | 2006-09-26 | 2017-11-01 | Celgene Corporation | 5-substituted quinazolinone derivatives as anti-cancer agents |
| CN101809037B (zh) | 2007-07-31 | 2014-01-15 | 瑞泽恩制药公司 | 人cd20的人抗体及其使用方法 |
| US20110243931A1 (en) | 2007-09-02 | 2011-10-06 | Thomas Friess | Combination therapy with type i and type ii anti-cd20 antibodies |
| CA2704710C (en) | 2007-09-26 | 2016-02-02 | Celgene Corporation | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising the same |
| TWI546290B (zh) | 2008-06-27 | 2016-08-21 | 賽基艾維洛米斯研究股份有限公司 | 雜芳基化合物及其用途 |
| EP2436387B1 (en) | 2009-05-25 | 2018-07-25 | Celgene Corporation | Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex |
| MX2012010367A (es) | 2010-03-12 | 2012-11-23 | Celgene Corp | Metodos para el tratamiento de linfomas no hodgkin que usan lenalidomida y biomarcadores de genes y proteinas como un predictor. |
| JP6068340B2 (ja) * | 2010-08-10 | 2017-01-25 | セルジーン アヴィロミクス リサーチ， インコーポレイテッド | Ｂｔｋ阻害剤のベシル酸塩 |
| EP3025715A1 (en) * | 2011-03-11 | 2016-06-01 | Celgene Corporation | Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione |
| JP6016892B2 (ja) * | 2011-04-29 | 2016-10-26 | セルジーン コーポレイション | セレブロンを予測因子として使用する癌及び炎症性疾患の治療方法 |
| JP2014532658A (ja) * | 2011-10-28 | 2014-12-08 | セルジーン アヴィロミクス リサーチ， インコーポレイテッド | ブルトン型チロシンキナーゼ疾患または障害を治療する方法 |
-
2014
- 2014-05-02 WO PCT/US2014/036520 patent/WO2014179661A1/en not_active Ceased
- 2014-05-02 TW TW103115872A patent/TW201534305A/zh unknown
- 2014-05-02 US US14/268,439 patent/US9119854B2/en not_active Expired - Fee Related
- 2014-05-02 EP EP14727340.3A patent/EP2991651A1/en not_active Withdrawn
- 2014-05-02 JP JP2016512061A patent/JP2016521280A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016521280A5 (enExample) | ||
| JP2016516821A5 (enExample) | ||
| ZA202502152B (en) | Crystalline forms of a bruton's tyrosine kinase inhibitor | |
| CY1120248T1 (el) | Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου | |
| MX2017012411A (es) | Co-cristales de un inhibidor de tirosina cinasa de bruton. | |
| JP2016523974A5 (enExample) | ||
| JP2015508103A5 (enExample) | ||
| AR107751A1 (es) | Composiciones de forma de dosificación que comprenden un inhibidor de tirosina cinasa de bruton | |
| CU20130133A7 (es) | Sales de 2,3- dihidroimidazo[1,2- c] quinazolinas sustituda | |
| MX2016004342A (es) | Formulaciones de (s)-3-(4-((4-morfolinometil)bencil)oxi)-1-oxoisoi ndolin-2-il)piperidin-2,6-diona. | |
| RU2021102805A (ru) | 4,6-ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ | |
| JP2014065696A5 (enExample) | ||
| RU2016110874A (ru) | Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний | |
| JOP20190233A1 (ar) | نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون | |
| ES2688809T3 (es) | Combinaciones de compuestos inhibidores de AKT y MEK para tratar el cáncer | |
| BR112019006228A2 (pt) | tratamento de câncer de próstata | |
| JP2016529285A5 (enExample) | ||
| JP2017514806A5 (enExample) | ||
| MX2020013157A (es) | Métodos de tratamiento de afecciones relacionadas con el receptor s1p1. | |
| WO2014081712A3 (en) | Methods of treating a disease or disorder associated with bruton's tyrosine kinase | |
| RU2015145997A (ru) | Противоопухолевое лекарственное средство, включающее низкодозированный гидрохлорида иринотекана гидрат | |
| RU2017124371A (ru) | Комбинация производного 6-оксо-1,6-дигидро-пиридазина, обладающего противораковой активностью, с производным хиназолина | |
| JP2013528215A5 (enExample) | ||
| MX2019015177A (es) | Formulaciones farmaceuticas de n-(2-(2-(dimetilamino)etoxi)-4-meto xi-5((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amino)fenil)acrilam ida y las sales de ellas. | |
| WO2006135713A2 (en) | Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators and a farnesyl transferase inhibitor |